The glycan carbohydrate antigen 19-9 (CA19-9), also known as sialic acid-LewisA, plays a crucial role in the process of intercellular recognition. Due to the high sensitivity and specificity of CA19-9 for pancreatic cancer, CD BioGlyco provides glyco-biomarker CA19-9 detection service through various methods to help researchers explore new therapies for pancreatic cancer.
Pancreatic ductal adenocarcinoma is the leading cause of cancer-related death and has the lowest survival rate of any solid cancer. The discovery of biomarkers for early detection of pancreatic cancer is an urgent need to improve survival, although studies evaluating biomarkers for early detection are rarely performed using samples from patients with the preclinical disease. It has been reported that CA19-9 is one of the most important and widely used glyco-biomarkers for pancreatic cancer.
CA19-9 can be used as an adjuvant diagnostic indicator for pancreatic cancer, gallbladder cancer and other malignancies. This antigen exists in the pancreatic, gallbladder, liver and intestinal tissues of embryonic fetuses, and the content in normal human tissues is very low. In the serum of patients with malignant tumors of the digestive tract, especially pancreatic cancer and gallbladder cancer, the content of CA 19-9 is significantly increased. But it is mainly used as an indicator for disease monitoring and predicting recurrence rather than early diagnosis. In addition, CA19-9 is useful for the differential diagnosis of gastrointestinal diseases (e.g. pancreatic cancer and pancreatitis, gastric cancer and gastric ulcer).
Fig.1 Illustration of the preparation process for MGNRsCA19‑9, MGNRsMUC1, colorimetric immunosensor, and the detection procedures of CA19-9 and MUC1 based on the decolorization of MO by MGNRs in the presence of NaBH4. (Li, 2019)
CD BioGlyco offers multiple methods for detecting CA 19-9 in associated body fluids in small quantities for cancer diagnosis. The methods we provide include but are not limited to:
CD BioGlyco is dedicated to detecting a range of biomarkers including CA19-9 for early cancer diagnosis in small sample sizes, and we offer a wide range of services to meet your research needs. If you are interested in our services, please feel free to contact us.